Chardan Capital Maintains Buy on MeiraGTx Hldgs, Lowers Price Target to $35

Written by Emily J. Thompson, Senior Investment Analyst

MGTX0%

Source: Benzinga

Updated: May 14 2025

0mins

Source: Benzinga

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MGTX?" and start using high-conviction signals backed by rigorous historical data.

MGTX

$7.74+Infinity%1D

Analyst Views on MGTX

Wall Street analysts forecast MGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGTX is 21.50 USD with a low forecast of 14.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Analyst Rating

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.740

Low

14.00

Averages

21.50

High

30.00

Current: 7.740

Low

14.00

Averages

21.50

High

30.00

BofA

Buy

downgrade

$15 -> $14

2026-01-06

Reason

BofA

Price Target

$15 -> $14

AI Analysis

2026-01-06

downgrade

Buy

Reason

BofA lowered the firm's price target on MeiraGTx to $14 from $15 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

H.C. Wainwright

Mitchell Kapoor

Buy

initiated

$20

2025-11-24

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$20

2025-11-24

initiated

Buy

Reason

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of MeiraGTx with a Buy rating and $20 price target. The firm has conviction that AAV-AQP1 for radiation-induced xerostomia is one of the most "risk-mitigated late-stage gene therapy programs in development." It recommends buying the shares ahead of the pivotal data in late 2026 or early 2027.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MGTX

Unlock Now

About MGTX

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for MGTX?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy MGTX?

Get Started Free

Top News

Eli Lilly Enhances Genetic Eye Disease Pipeline Through Collaboration with MeiraGTx on Gene Therapy

Nov 10 2025Benzinga

MeiraGTx and Eli Lilly Collaboration: MeiraGTx Holdings has entered a strategic partnership with Eli Lilly, granting exclusive rights to its AAV-AIPL1 program for treating Leber congenital amaurosis 4, with an upfront payment of $75 million and potential milestone payments exceeding $400 million.
Clinical Success of AAV-AIPL1: Clinical trials showed that all 11 children treated with AAV-AIPL1 gained vision, with additional improvements in communication, behavior, learning, and social integration.
Riboswitch Technology: The collaboration includes access to MeiraGTx’s riboswitch technology for gene editing in ophthalmology, allowing precise control over therapeutic protein production through oral dosing.
SanegeneBio and Eli Lilly Partnership: SanegeneBio has also partnered with Eli Lilly to advance RNAi candidates for metabolic diseases, with potential milestone payments up to $1.2 billion and a focus on developing therapies that can be administered infrequently.

an image of Eli Lilly Enhances Genetic Eye Disease Pipeline Through Collaboration with MeiraGTx on Gene Therapy

Eli Lilly Partners with MeiraGTx to Create Gene Therapies for Ocular Disorders

Nov 10 2025SeekingAlpha

Collaboration Announcement: MeiraGTx (MGTX) shares rose approximately 18% in premarket trading after announcing a strategic collaboration with Eli Lilly (LLY) to develop gene therapies for eye diseases, specifically targeting Leber congenital amaurosis 4 (LCA4).
Exclusive Rights and Financial Terms: Under the agreement, Eli Lilly will receive exclusive global rights to MGTX's AAV-AIPL1 gene therapy program and other gene therapy technologies, with MeiraGTx set to receive $75 million upfront and over $400 million based on milestone achievements, along with tiered royalties on future sales.

an image of Eli Lilly Partners with MeiraGTx to Create Gene Therapies for Ocular Disorders

Chardan Capital Maintains Buy on MeiraGTx Hldgs, Lowers Price Target to $35

Trade with 70% Backtested Accuracy

Analyst Views on MGTX

About MGTX

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

ISG Launches Research on Insurance Service Providers

Ecopetrol Nominates New Board Candidate

Eli Lilly Enhances Genetic Eye Disease Pipeline Through Collaboration with MeiraGTx on Gene Therapy

Eli Lilly Partners with MeiraGTx to Create Gene Therapies for Ocular Disorders

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch